Street View: Immunology strength holds at AbbVie despite aesthetics drag

AbbVie ABBV.N said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, which in 2024 yielded discounts of as much as 79%

Co raised its 2025 profit forecast, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped lift third-quarter results above estimates

Median PT of 31 brokerages covering the stock is $242.50, with an avg "buy" rating - LSEG data

AESTHETICS STRUGGLES CONTINUE

J.P.Morgan ("overweight," PT: $260) says the aesthetics segment continues to face headwinds, particularly as macro factors continue to impact consumer sentiment

However, sees the results highlighting continued strength/outperformance across ABBV's core franchises

Morgan Stanley ("overweight," PT: $261) says "another solid quarter for the immunology franchise, while aesthetics remains soft"

Adds that focus heading into 2026 is growth of Skyrizi vs. competition from J&J JNJ.N and ongoing pipeline diversification efforts

Wells Fargo ("overweight," PT: $260) says while competition is brewing in IL-23 space, ABBV could still grow a lot given under-penetration

BMO ("outperform," PT: $258) says AbbVie's immunology franchise's outperfomance needs to be maintained to keep investor interest